The symptoms experienced by those who suffer from chronic fatigue may be related to acute inflammation in the brain, according to a PET study published March 24 in the Journal of Nuclear Medicine.

The worldwide market for radiopharmaceuticals is expected to round out at a compound annual growth rate of 18.39 percent every year from 2012 through 2016, according to a report announced March 26 by research firm TechNavio.

Pharmaceutical company NeuroPhage has nailed $15 million in financing for therapeutic drugs for neurodegenerative disorders including Alzheimer’s disease and Parkinson's, the company announced March 25.

Type two diabetes definitively leads to neuronal injury, but the jury is still out whether it contributes to the buildup of beta-amyloid in the brain associated with Alzheimer’s disease, according to a study published March 20 by the Journal of Nuclear Medicine.

A community-wide evaluation of myocardial perfusion imaging (MPI) use throughout the Kaiser Permanente Northern California health system revealed an unexplainable 51 percent dip in MPI from 2006-2011, according to research published today in the Journal of the American Medical Association.

The Medical Imaging and Technology Alliance (MITA) has brought in Terri Wilson as the organization’s director of PET industry policy.

A major backer of the Alzheimer’s Association is pushing to change the way we categorize Alzheimer’s disease based on a brain study published in Neurology. The research places Alzheimer’s firmly in third place as a leading cause of death in America, instead of its current position of sixth.

The global breast imaging market is expected to rise at a compound annual growth rate of 15.37 percent until 2017 reaching a total worth of $5 billion, announced research firm RnRMarketResearch.com today.